12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes

IntroductionLipoxygenases (LOXs) have essential roles in stroke, atherosclerosis, diabetes, and hypertension. 12/15-LOX inhibition was shown to reduce infarct size and brain edema in the acute phase of experimental stroke. However, the significance of 12/15-LOX on neuroinflammation, which has an ess...

Full description

Bibliographic Details
Main Authors: Canan Cakir-Aktas, Ebru Bodur, Muge Yemisci, Klaus van Leyen, Hulya Karatas
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fncel.2023.1277268/full
_version_ 1797672433489018880
author Canan Cakir-Aktas
Ebru Bodur
Muge Yemisci
Muge Yemisci
Klaus van Leyen
Hulya Karatas
author_facet Canan Cakir-Aktas
Ebru Bodur
Muge Yemisci
Muge Yemisci
Klaus van Leyen
Hulya Karatas
author_sort Canan Cakir-Aktas
collection DOAJ
description IntroductionLipoxygenases (LOXs) have essential roles in stroke, atherosclerosis, diabetes, and hypertension. 12/15-LOX inhibition was shown to reduce infarct size and brain edema in the acute phase of experimental stroke. However, the significance of 12/15-LOX on neuroinflammation, which has an essential role in the pathophysiology of stroke, has not been clarified yet.MethodsIn this study, ischemia/recanalization (I/R) was performed by occluding the proximal middle cerebral artery (pMCAo) in mice. Either the 12/15-LOX inhibitor (ML351, 50 mg/kg) or its solvent (DMSO) was injected i.p. at recanalization after 1 h of occlusion. Mice were sacrificed at 6, 24, and 72-h after ischemia induction. Infarct volumes were calculated on Nissl-stained sections. Neurological deficit scoring was used for functional analysis. Lipid peroxidation was determined by the MDA assay, and the inflammatory cytokines IL-6, TNF-alpha, IL-1beta, IL-10, and TGF-beta were quantified by ELISA. The inflammasome proteins NLRP1 and NLRP3, 12/15-LOX, and caspase-1 were detected with immunofluorescence staining.ResultsInfarct volumes, neurological deficit scores, and lipid peroxidation were significantly attenuated in ML351-treated groups at 6, 24, and 72-h. ELISA results revealed that the pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha were significantly decreased at 6-h and/or 24-h of I/R, while the anti-inflammatory cytokines IL-10 and TNF-alpha were increased at 24-h or 72-h of ML351 treatment. NLRP1 and NLRP3 immunosignaling were enhanced at three time points after I/R, which were significantly diminished by the ML351 application. Interestingly, NLRP3 immunoreactivity was more pronounced than NLRP1. Hence, we proceeded to study the co-localization of NLRP3 immunoreactivity with 12/15-LOX and caspase-1, which indicated that NLRP3 was co-localized with 12/15-LOX and caspase-1 signaling. Additionally, NLRP3 was found in neurons at all time points but in non-neuronal cells 72 h after I/R.DiscussionThese results suggest that 12/15-LOX inhibition suppresses ischemia-induced inflammation in the acute and subacute phases of stroke via suppressing inflammasome activation. Understanding the mechanisms underlying lipid peroxidation and its associated pathways, like inflammasome activation, may have broader implications for the treatment of stroke and other neurological diseases characterized by neuroinflammation.
first_indexed 2024-03-11T21:29:59Z
format Article
id doaj.art-81bce9e14dd14720ac89431a64d72aaf
institution Directory Open Access Journal
issn 1662-5102
language English
last_indexed 2024-03-11T21:29:59Z
publishDate 2023-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cellular Neuroscience
spelling doaj.art-81bce9e14dd14720ac89431a64d72aaf2023-09-27T09:52:12ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022023-09-011710.3389/fncel.2023.1277268127726812/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomesCanan Cakir-Aktas0Ebru Bodur1Muge Yemisci2Muge Yemisci3Klaus van Leyen4Hulya Karatas5Institute of Neurological Sciences & Psychiatry, Hacettepe University, Ankara, TürkiyeDepartment of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, TürkiyeInstitute of Neurological Sciences & Psychiatry, Hacettepe University, Ankara, TürkiyeDepartment of Neurology, Faculty of Medicine, Hacettepe University, Ankara, TürkiyeNeuroprotection Research Laboratory, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesInstitute of Neurological Sciences & Psychiatry, Hacettepe University, Ankara, TürkiyeIntroductionLipoxygenases (LOXs) have essential roles in stroke, atherosclerosis, diabetes, and hypertension. 12/15-LOX inhibition was shown to reduce infarct size and brain edema in the acute phase of experimental stroke. However, the significance of 12/15-LOX on neuroinflammation, which has an essential role in the pathophysiology of stroke, has not been clarified yet.MethodsIn this study, ischemia/recanalization (I/R) was performed by occluding the proximal middle cerebral artery (pMCAo) in mice. Either the 12/15-LOX inhibitor (ML351, 50 mg/kg) or its solvent (DMSO) was injected i.p. at recanalization after 1 h of occlusion. Mice were sacrificed at 6, 24, and 72-h after ischemia induction. Infarct volumes were calculated on Nissl-stained sections. Neurological deficit scoring was used for functional analysis. Lipid peroxidation was determined by the MDA assay, and the inflammatory cytokines IL-6, TNF-alpha, IL-1beta, IL-10, and TGF-beta were quantified by ELISA. The inflammasome proteins NLRP1 and NLRP3, 12/15-LOX, and caspase-1 were detected with immunofluorescence staining.ResultsInfarct volumes, neurological deficit scores, and lipid peroxidation were significantly attenuated in ML351-treated groups at 6, 24, and 72-h. ELISA results revealed that the pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha were significantly decreased at 6-h and/or 24-h of I/R, while the anti-inflammatory cytokines IL-10 and TNF-alpha were increased at 24-h or 72-h of ML351 treatment. NLRP1 and NLRP3 immunosignaling were enhanced at three time points after I/R, which were significantly diminished by the ML351 application. Interestingly, NLRP3 immunoreactivity was more pronounced than NLRP1. Hence, we proceeded to study the co-localization of NLRP3 immunoreactivity with 12/15-LOX and caspase-1, which indicated that NLRP3 was co-localized with 12/15-LOX and caspase-1 signaling. Additionally, NLRP3 was found in neurons at all time points but in non-neuronal cells 72 h after I/R.DiscussionThese results suggest that 12/15-LOX inhibition suppresses ischemia-induced inflammation in the acute and subacute phases of stroke via suppressing inflammasome activation. Understanding the mechanisms underlying lipid peroxidation and its associated pathways, like inflammasome activation, may have broader implications for the treatment of stroke and other neurological diseases characterized by neuroinflammation.https://www.frontiersin.org/articles/10.3389/fncel.2023.1277268/full12/15-LOXstrokeischemia-recanalizationneuroinflammationinflammasomeNLRP3
spellingShingle Canan Cakir-Aktas
Ebru Bodur
Muge Yemisci
Muge Yemisci
Klaus van Leyen
Hulya Karatas
12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
Frontiers in Cellular Neuroscience
12/15-LOX
stroke
ischemia-recanalization
neuroinflammation
inflammasome
NLRP3
title 12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
title_full 12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
title_fullStr 12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
title_full_unstemmed 12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
title_short 12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
title_sort 12 15 lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes
topic 12/15-LOX
stroke
ischemia-recanalization
neuroinflammation
inflammasome
NLRP3
url https://www.frontiersin.org/articles/10.3389/fncel.2023.1277268/full
work_keys_str_mv AT canancakiraktas 1215lipoxygenaseinhibitionattenuatesneuroinflammationbysuppressinginflammasomes
AT ebrubodur 1215lipoxygenaseinhibitionattenuatesneuroinflammationbysuppressinginflammasomes
AT mugeyemisci 1215lipoxygenaseinhibitionattenuatesneuroinflammationbysuppressinginflammasomes
AT mugeyemisci 1215lipoxygenaseinhibitionattenuatesneuroinflammationbysuppressinginflammasomes
AT klausvanleyen 1215lipoxygenaseinhibitionattenuatesneuroinflammationbysuppressinginflammasomes
AT hulyakaratas 1215lipoxygenaseinhibitionattenuatesneuroinflammationbysuppressinginflammasomes